Clinical trials to determine the efficacy of a drug are costly, particularly when there are many subtypes of a certain disease that could vary greatly in their response to a molecule. In this interview, Brian Van Ness, PhD, of the University of Minnesota, Minneapolis, MN, gives an overview of a specialised core facility that allows for the modelling of drug responses by multiple myeloma (MM) subtype through the identification of gene expression patterns in individualized cells, and can help identify the subclonal architecture of heterogeneous tumors. This interview was recorded at the Myeloma 2017 meeting in Edinburgh, UK.
Molecular modelling of drug efficacy in multiple myeloma
